Long-acting low molecule heparin intraocular sustained-release system

Abstract

The invention relates to an ophthalmic controlled release system of long-action low molecular heparin which comprises the low molecular heparin as drug and a drug carrier made from synthesized or natural biodegradable high molecular materials and is characterized in that the proportion range of the low molecular heparin and the drug carrier is (1:8) to (5:1); the average molecular mass of the lowmolecular heparin is less than 8000 Dalton; the molecules less than 8000 Dalton, the salt compounds of the low molecular heparin such as sodium salt, calcium salt and kali salt included, take up not less than 60 percent of the total molecules of the low molecular heparin; the synthesized or natural biodegradable high molecular materials are polyglycolic acid and gelatin or bletilia striata gelatinrespectively. The ophthalmic controlled release system of long-action low molecular heparin can effectively inhibit the proliferation and migration of lenticular epithelia and fibroblasts in eyes, reduce fibrinous exudates post operation, alleviate inflammatory reaction post operation and prevent posterior capsular opacification, thereby inhibiting the occurrence of after-cataract; meanwhile, theophthalmic controlled release system of long-action low molecular heparin inhibits the proliferation of retinal pigment epithelium and fibroblasts, thus inhibiting the proliferative vitreoretinopathy(PVR).

Description

technical field [0001] The invention relates to a pharmaceutical preparation for preventing and treating post-cataract, in particular to an intraocular implanted drug sustained-release preparation long-acting low-molecular-weight heparin intraocular sustained-release system with high safety and certain therapeutic effect. Background technique [0002] According to the standards of the World Health Organization (WHO) on blindness and visual impairment, the prevalence of blindness in my country is 0.43% to 0.56%, and it is estimated that there are at least 6.7 million blind people in the country. The main cause of blindness is cataract, which accounts for about 40.00% to 70.00% of the total number of blind people in various places. The cumulative amount of cataract blindness is about 3 million people, and about 400,000 new cataracts are born every year. With the development of microsurgical techniques, the clinical application of modern extracapsular cataract extraction and ph...

AI Technical Summary

Problems solved by technology

The main reason for heparin-induced bleeding is that it has a strong effect on coagulation factors FIIa and FXa, while low-molecular-weight heparin is mainly dextran with less than 18 sugar units, which only retains the anti-FXa effect, but has a very strong effect on FIIa factor. It is small, so it overcomes the shortcoming that heparin is easy to cause bleeding. It is gradually replacing heparin in clinical practice and is safely used in the treatment of cardiovascular and cerebrovascular diseases. However, it is currently only used in clinical perfusion fluid and subconjunctival injection in ophthalmology. Long-acting low-molecular-weight heparin intraocular sustained-release preparations with medicinal functions have not yet come out

Images